Company intelligence / Profile preview

FreezeM

Kibbutz Nachshonim, Central, Israelfreezem.com ↗

Ownership: Private
Development stage: Commercial

Overview

FreezeM has developed patented biotechnology enabling the large-scale, reliable supply of "paused" Black Soldier Fly larvae ("PauseM®"), which can be shipped globally with high survival rates. This innovation decouples breeding from rearing, streamlining insect protein production for animal feed and waste management. The company has raised significant funding to expand its commercial operations across Europe and Israel, with strong early adoption by industrial partners[2][5].

Modalities: Not applicable
Industry: Non-Drug Biotech

Partnerships

Hermetia Deutschland GmbH (strategic partnership for European BSF breeding facility)European Innovation Council Fund/EIC Fund [investor & partner]

Beyond the preview

Go deeper on FreezeM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FreezeM.

Explore the full profile